Yifan Pharmaceutical (002019): F627 domestic phase III clinical success and future prospects to improve performance

Yifan Pharmaceutical (002019): F627 domestic phase III clinical success and future prospects to improve performance F627 China Phase III clinical trial has indeed achieved safety and safety targets. The domestic phase III clinical trial started in May 17th. It is a domestic multi-center, randomized, open, and properly controlled clinical trial protocol. The first trial was […]

Read MoreRead More

Pay close attention to system construction and continue to play the goose effect of listed companies

Pay close attention to system construction and continue to play the goose effect of listed companies Huang Yanming, director of Guotai Junan Securities Research Institute, Changchun Hua, chief global economist of Guotai Junan Securities Research Institute, May 11th, at the 2019 Annual Meeting of the China Listed Companies Association.The speech on “The Foundation of Vigorous […]

Read MoreRead More

CNOOC (601808): 2Q19 performance exceeded expectations; strong earnings growth momentum maintained to maintain winning industry

CNOOC (601808): 2Q19 performance exceeded expectations; strong earnings growth momentum maintained to maintain winning industry Performance review maintains outperforming industry 2Q19 results exceeding our expectations of 2Q19 results announced by CNOOC: According to Chinese accounting standards, the company’s revenue increased by 62% to 7.7 billion US dollars, and net profit growth increased more than twice […]

Read MoreRead More

Daqin Railway (601006) Annual Report Comments: Performance Meets Expectations Still Has Certain Defensive Value

Daqin Railway (601006) Annual Report Comments: Performance Meets Expectations Still Has Certain Defensive Value Profit growth in 2018 8. 99%, 1Q19 earnings decrease 4. 06%, performance in line with expectations On April 24, the company released its 2018 annual report and 2019 first quarter report. According to the restatement statement, the net profit attributable to […]

Read MoreRead More

Shanghai Bank (601229) 1H19 Results Express Review: Earnings Increase Faster, ROE Up

Shanghai Bank (601229) 1H19 Results 重庆耍耍网 Express Review: Earnings Increase Faster, ROE Up Event: On July 24th, the Bank of Shanghai disclosed the semi-annual results report for 2019. In 1H19, net profit attributable to mother was 107. 140,000 yuan, a year-on-year increase of +14. 32%; revenue 251. 510,000 yuan, a year-on-year increase of +27. 35%; […]

Read MoreRead More

Yutong Bus (600066): Continued High R & D Investment Leads and Additional Stability

Yutong Bus (600066): Continued High R & D Investment Leads and Additional Stability The company’s highlights are solid and the bus lineup is rich. From the perspective of sales volume: According to the company’s 2018 annual report data, in 2018, the incremental sales of medium-sized passenger cars were 8 respectively. 450,000 vehicles, 6. 690,000 vehicles, […]

Read MoreRead More

Weifu Hi-Tech (000581): Implementation of National Six Standards will strengthen the company’s product technology advantages

Weifu Hi-Tech (000581): Implementation of National Six Standards will strengthen the company’s product technology advantages Large asset impairment / declining gross profit margin affected last year’s performance Weifu Hi-Tech achieved total revenue of 87 in 2018. 200 million, down slightly by 3 previously. 3%; net profit attributable to mothers was 2.4 billion, down 6 from […]

Read MoreRead More